The identification of the genes associated with chromosomal translocation breakpoints has fundamentally changed understanding of the molecular basis of hematological malignancies. By contrast, the study of chromosomal deletions has been hampered by the large number of genes deleted and the complexity of their analysis. We report the generation of a mouse model for human 5q-syndrome using large-scale chromosomal engineering. Haploinsufficiency of the Cd74-Nid67 interval (containing Rps14, encoding the ribosomal protein S14) caused macrocytic anemia, prominent erythroid dysplasia and monolobulated megakaryocytes in the bone marrow. These effects were associated with defective bone marrow progenitor development, the appearance of bone marrow cells expressing high amounts of the tumor suppressor p53 and increased bone marrow cell apoptosis. Notably, intercrossing with p53-deficient mice completely rescued the progenitor cell defect, restoring common myeloid progenitor and megakaryocytic-erythroid progenitor, granulocyte-monocyte progenitor and hematopoietic stem cell bone marrow populations. This mouse model suggests that a p53-dependent mechanism underlies the pathophysiology of the 5q-syndrome.
a r t i c l e s 5q-syndrome was first described in 1974 as a consistent association of the deletion of the long arm of chromosome 5 (del(5q)) with hematological abnormalities: macrocytosis, anemia, normal or high platelet count and hypolobulated megakaryocytes in the bone marrow 1 . The disease has a female preponderance and a low rate of transformation to acute myeloid leukemia (AML), although most affected individuals become transfusion dependent, resulting in considerable morbidity 2 . Recently, the immunomodulatory drug lenalidomide has been shown to induce cytogenetic remission 3 , although its mode of action remains to be fully determined.
5q-syndrome is recognized as a distinct clinical entity according to the World Health Organization classification and is defined by a medullary blast count of <5% and the presence of the del(5q) deletion as the sole karyotypic abnormality 4 . The deletion involved in 5q-syndrome is typically a large interstitial deletion and contains a number of genes involved in hematopoiesis 5 . The del(5q) deletion is also commonly found in other myelodysplastic syndromes and in AML (10-15% of all affected individuals), although it is cytogenetically indistinguishable across these disorders. The del(5q) deletion in 5q-syndrome is widely believed to mark the location for a tumor suppressor gene, the loss of which may affect key processes such as growth control and normal hematopoiesis 5, 6 .
The commonly deleted region (CDR) in 5q− syndrome was first identified on the basis of fine mapping of the chromosomes of individuals with cytogenetically small deletions 7 , and it was subsequently narrowed to approximately 1.5 Mb between 5q31 and 5q32, flanked by D5S413 and the gene encoding glycine receptor α-1 (GLRA1) 8 . The CDR contains 24 known and 16 predicted genes, 33 of which were found to be expressed in CD34 + cells and which represent candidate genes for 5q-syndrome 8 . The 5q-syndrome CDR is distinct from a more proximal 5q-CDR that has been associated with more advanced myelodysplastic syndromes and AML 9 .
To date, studies have failed to identify mutations within the retained alleles or potential submicroscopic homozygous deletions in the CDR 10 . This suggests either that haploinsufficiency promotes 5q-syndrome or that a retained tumor suppressor allele has undergone epigenetic inactivation 11, 12 .
Several potential candidate genes for 5q-syndrome map within the CDR, including those encoding fat tumor suppressor homolog-2 (FAT2), a homolog of the Drosophila fat tumor suppressor protein 8 ; secreted protein acidic and rich in cysteine (SPARC), a matricellular glycoprotein that is expressed primarily in tissues that undergo continual turnover or at sites of injury and disease 13, 14 ; and RPS14, a component of the 40S ribosomal subunit. Haploinsufficiency of RPS14 has been described in CD34 + cells of individuals with 5q-syndrome 10 . Indeed, an RNAi screen in CD34 + human hematopoietic progenitor cells identified RPS14 as a key factor in erythroid development in vitro 15 . These results suggest that 5q-syndrome might have an etiology related to the RPS19-dependent pathology of Diamond Blackfan anemia 16 .
Recently, researchers have used chromosome engineering to identify the tumor suppressor gene encoding chromodomain helicase DNA binding protein-5 (CHD5) at human 1p36 (ref. 17) . The only reported large-scale analysis of a targeted deletion of genes syntenic A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome a r t i c l e s to human 5q generated a 450-kb region on mouse chromosome 11 (outside of the CDR of 5q-syndrome). This analysis showed that the genes between those encoding interferon regulatory factor-1 (Irf1) and granulocyte-macrophage colony-stimulating factor (Csfgm) are not involved in 5q-syndrome 18 .
To enable progress toward understanding 5q-syndrome, we attempted to generate a mouse model for this disease. We used a comprehensive chromosomal engineering approach using Cre-loxP recombination to delete the syntenic regions in the mouse equivalent to the 5q-CDR and thereby identify genes that alter normal hematopoiesis due to haploinsufficiency. We generated a mouse strain with a deletion on chromosome 18 flanked by the Cd74 gene and the nerve growth factor-induced differentiation clone 67-encoding gene (Nid67, the official gene symbol in the mouse is 2010002N04Rik) that shows a macrocytic anemia, with dysplastic features in the bone marrow. We found that these changes correlated with an increase in a population of highly p53-positive cells in the bone marrow and elevated apoptosis. Intercrossing of these mice with p53-deficient mice resulted in a reversal of the deficit in hematopoietic progenitor cell development, thereby revealing a mechanistic involvement of p53 in 5q-syndrome.
RESULTS

Cd74-Nid67 deletion causes a 5q-syndrome-like phenotype
The CDR on the long arm of human chromosome 5 is divided into two regions of synteny on mouse chromosomes 11 and 18, with complete conservation of gene order and orientation (Fig. 1a) .
To narrow down the CDR, we used a method in embryonic stem cells to generate a series of nested random deletions on chromosome 11 (ref. 19) extending in both directions from the Sparc gene, ranging from a few kilobases to over 5 Mb (Supplementary Fig. 1a-c) . We selected two deletions for further analysis. Clone 91 contained a deletion extending from Sparc to beyond the gene encoding glutathione peroxidase-3 (Gpx3), a deletion of at least 0.7 Mb but less than 1.5 Mb (Fig. 1b) . Clone 2 contained a deletion extending from Sparc to the gene encoding neuromedin U 2 receptor (Nmu2r), a deletion of approximately 0.5 Mb (Fig. 1c) . In combination, these deletions remove all of the genes mapping to the syntenic region on mouse chromosome 11 that are commonly deleted in 5q-syndrome 8 . However, we observed no appreciable changes in the hematopoietic system including RBC number and hemoglobin concentration ( Supplementary Fig. 1d ,e and data not shown) in heterozygote mice carrying these individual deletions, even at 12-14 months of age. We were unable to generate mice homozygous for either deletion (data not shown).
Within this region, both Sparc and Fat2 have been proposed as candidate genes for 5q-syndrome 8, 14 . To assess their role in hematopoiesis, we generated both Sparc −/− mice ( Supplementary Fig. 1a-c) and Fat2 −/− mice ( Supplementary Fig. 2a-c) , but found no evidence for Sparc or Fat2 having roles in the development of red blood cells (RBCs) or platelets ( Supplementary Fig. 1f and data not shown).
The syntenic region on mouse chromosome 18 corresponding to the CDR defined in 5q-syndrome extends from Nid67 to the gene encoding adrenergic β2-receptor (Adrb2) (Fig. 1a) . We subdivided 
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+/+ ; By contrast, deletion of the interval extending from Cd74 to Nid67, achieved by targeting loxP sites to both genes in cis and intercrossing the resultant mice with the Lmo2Cre knock-in mice ( Fig. 1e and Supplementary Fig. 4a-c) , resulted in striking perturbations to the hematopoietic system, as described below.
Deletion of the Cd74-Nid67 interval causes macrocytic anemia
Blood parameters were analyzed from cohorts of four genotypes: Cd74 +/lox ; Nid67 +/lox ; Lmo2Cre + mice; Cd74 +/+ ; Nid67 +/+ ; Lmo2Cre + mice; Cd74 +/lox ; Nid67 +/lox ; Lmo2Cre − mice; and Cd74 +/+ ; Nid67 +/+ ; Lmo2Cre − mice. We observed a striking 40-50% reduction in the number of circulating RBCs in Cd74 +/lox ; Nid67 +/lox ; Lmo2Cre + mice (hereafter referred to as Cd74-Nid67-deleted mice) compared to controls ( Fig. 2a) . Furthermore, hemoglobin concentrations were significantly decreased (P ≤ 0.0020) in Cd74-Nid67-deleted mice (Fig. 2b) . These findings correlated with the appearance of pencil-shaped cells in the blood of the anemic mice ( Supplementary Fig. 5a ).
Peripheral blood RBCs in Cd74-Nid67-deleted mice were larger than in control mice, as assessed by mean corpuscular volume (Fig. 2c) , mean RBC distribution width ( Fig. 2d) and light microscopy (Fig. 2e) . Flow cytometric analysis showed that RBCs, defined by staining for the cell surface marker TER119, in the bone marrow of Cd74-Nid67-deleted mice were also larger in size than those in control mice (Fig. 2f) , indicating the presence of abnormally large RBC (macrocytes). These data indicate that deletion of the Cd74-Nid67 interval leads to macrocytic anemia, a key characteristic of 5q-syndrome. In addition, we observed a modest thrombocytopenia in the blood of Cd74-Nid67-deleted mice (Fig. 3a) , although we also observed a reduction in the number of platelets in Cd74 +/+ ; Nid67 +/+ ; Lmo2Cre + control mice compared to wild-type mice (Fig. 3a) . Although blood lymphocyte and monocyte numbers were not appreciably reduced ( Supplementary Fig. 5b,c) , total granulocyte numbers were lower in the blood of Cd74-Nid67-deleted mice compared to controls (Supplementary Fig. 5d ), probably owing to a deficit in eosinophils and polymorphonuclear leukocytes (Fig. 3b) .
Cd74-Nid67 deletion impairs progenitor cell production
We observed a reproducible 50-60% reduction in the numbers of cells flushed from the femurs of Cd74-Nid67-deleted mice compared to controls (Fig. 3c) , and bone marrow sections from Cd74-Nid67-deleted mice ranged from mildly to highly hypocellular (Fig. 3d) . Hypocellularity resulted from decreases in cell number across the hematopoietic cell lineages, as the relative proportions of these cell types remained relatively similar for all genotypes (Fig. 3e) . A notable exception to this observation was the elevated proportion of mast cells in the bone marrow of Cd74-Nid67-deleted mice (Fig. 3e and Fig. 4) , the reason for which is unclear. However, the principal bone marrow abnormalities that we observed were a prominent dyserythropoiesis and monolobulation of megakaryocytes, as assessed in cytospins (Fig. 4a-h ) and sections (data not shown).
To ascertain whether the reduction in peripheral RBC numbers resulted from a deficit in the proliferation and differentiation of erythroid and myeloid progenitors, we performed assays for erythroid colony-forming units (CFU-E), granulocyte/macrophage CFUs (CFU-GM) and megakaryocyte CFUs (CFU-MK). The numbers of CFU-E (Fig. 5a) , CFU-GM (Fig. 5b) and CFU-MK (Fig. 5c) were considerably depressed in the bone marrow of Cd74-Nid67-deleted mice. These data indicate that deletion of the Cd74-Nid67 interval results in a deficit in the hematopoietic progenitor population. (Fig. 3e) .
Candidate genes in the Cd74-Nid67 interval The deleted Cd74-Nid67 interval contains eight known genes; these genes encode CD74, an immunoregulatory protein; Rps14; N-deacetylase/N-sulfotransferase 1 (Ndst1), a heparin sulfate-modifying enzyme; synaptopodin (Synpo), an actin-binding protein; myozenin-3 (Myoz3), a cytoskeletal component; RNA-binding motif protein-22 (Rbm22), an RNA-binding protein; dynactin-4 (Dctn4) (Supplementary Fig. 6a,b) . Of the remaining six genes, Rps14, encoding a component of the 40S ribosome, has recently been proposed to have a key role in 5q-syndrome on the basis of in vitro data 15 .
Cd74-Nid67 deletion induces p53 expression and apoptosis
Dysregulation of ribosome biogenesis resulting from insufficiency of ribosomal subunits has been shown to activate a p53 checkpoint and regulate developmental pathways [24] [25] [26] . To determine whether haploinsufficiency of Rps14 (or its flanking neighbors) within the Cd74-Nid67 interval could lead to the induction of p53, we assessed intracellular p53 abundance in bone marrow cells. Notably, a greater number of bone marrow cells from Cd74-Nid67-deleted mice stained for elevated p53 compared to controls (P ≤ 0.0024; Fig. 5d,e) . In bone marrow samples from Cd74-Nid67-deleted mice that showed elevated p53 expression, concurrent staining for c-Kit showed that the p53-positive cells had predominantly intermediate levels of c-Kit staining, suggesting that they may represent immature progenitor cells (Fig. 5e) .
Stabilization of p53 leads to cell-cycle arrest and apoptosis 27, 28 . Apoptosis, as assessed by annexin V staining, was elevated in bone marrow cells isolated from Cd74-Nid67-deleted mice compared to controls (Fig. 5f) . However, this difference did not achieve statistical significance in all experiments, as we observed variation in the number of cells staining due to the range in disease severity observed in the mice and the very low frequency of progenitor cells within the bone marrow.
Taken together, these data suggest that elevated p53 in the hematopoietic progenitors of Cd74-Nid67-deleted mice induces cell death, resulting in a deficit in the erythroid lineage. 
a r t i c l e s
Cd74-Nid67 deletion causes progenitor cell deficiencies
To assess the effect of deletion of the Cd74-Nid67 interval on the development of specific hematopoietic progenitor populations, we stained bone marrow samples for markers of common myeloid progenitors (CMPs) and megakaryocytic-erythroid progenitors (MEPs) (both Lin − c-Kit high Stem cell antigen-1 (Sca-1) − CD16/CD32 low ) (the antibody used recognizes both CD16 and CD32) and granulocyte-monocyte progenitors (GMPs, Lin − c-Kit high Sca-1 − CD16/CD32 high ). Bone marrow from Cd74-Nid67-deleted mice had a striking deficit in the CMP-MEP and GMP lineages compared to controls (Fig. 6a) . Analysis of interleukin-7 receptor-α-negative (IL-7Rα − ) Lin − c-Kit high Sca-1 + hematopoietic stem cells (HSCs) revealed a notable scarcity of these cells in the bone marrow of Cd74-Nid67-deleted mice (Fig. 6b) . We observed similar results in the spleen of these mice, although the proportion of progenitors was considerably lower compared to the bone marrow (Supplementary Fig. 7a ). The use of SLAM (signaling lymphocyte attractant molecule) markers 29 confirmed the reduction in number of HSCs (CD150 + CD48 − CD244 − ) and more committed CD150 − CD48 − lineages (data not shown).
Inhibition of p53 rescues the progenitor deficit
To test whether inhibition of the p53 pathway could ameliorate the anemia and dysplasia observed in Cd74-Nid67-deleted mice, we intercrossed these mice with Trp53 −/− mice. We then crossed Cd74 +/lox ; Nid67 +/lox ; Lmo2Cre + ; Trp53 +/− mice with Cd74 +/+ ; Nid67 +/+ ; Trp53 +/− mice to generate mice with the twelve genotypes shown in Figure 6 . Absence of p53 in Cd74-Nid67-deleted mice completely reversed their deficit in the CMP-MEP and GMP populations, as observed by comparing these cell populations in Cd74 +/lox ; Nid67 +/lox ; Lmo2Cre + ; Trp53 −/− to Cd74 +/lox ; Nid67 +/lox ; Lmo2Cre + ; Trp53 +/+ mice, with heterozygous mutation of p53 resulting in an intermediate phenotype 
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-/ - a r t i c l e s (Fig. 6a) . Similarly, absence of p53 resulted in complete rescue of the HSC population in Cd74-Nid67-deleted mice; heterozygous mutation of p53 again had an intermediate phenotype (Fig. 6b) . Similar effects on progenitor cell populations were observed in the spleen (Supplementary Fig. 7a ). Deletion of Trp53 also completely rescued deficits in the CFU-E (Fig. 6c) and CFU-GM (Fig. 6d) activities in the bone marrow of Cd74-Nid67-deleted mice, and we obtained similar results in the spleen (Supplementary Fig. 7b,c) .
Because the presence of the Lmo2Cre allele in combination with the absence of p53 resulted in a decrease in RBC numbers to levels equivalent to those in the Cd74-Nid67-deleted mice, we were unable to determine whether inhibition of p53 could reverse the deficit in RBC numbers observed in Cd74-Nid67-deleted mice (Supplementary Fig. 8a ). We obtained similar results for hemoglobin levels (data not shown). However, we did find that the absence of p53 reversed the increased mean corpuscular volume observed in Cd74-Nid67-deleted mice (Supplementary Fig. 8b) . Deletion of Trp53 also resulted in an increase in platelet numbers, reversing the thrombocytopenia (Supplementary Fig. 8c ) and bone marrow dysplasia (data not shown) observed in Cd74-Nid67-deleted mice. Thus, removal of p53 reverses many of the hematopoietic deficits induced by deletion of the Cd74-Nid67 interval, indicating that p53 has a crucial role in maintaining the number and activities of hematopoietic progenitor cells in mice carrying this deletion.
DISCUSSION
We report here the generation of a mouse model for human 5q-syndrome, to our knowledge the first example of a mouse model for a human myelodysplasia involving a large-scale chromosomal deletion. We show that segmental haploidy (generated using Cre-loxP-mediated chromosomal engineering) of a locus (or loci) residing in the interval between Cd74 and Nid67, syntenic with a region within the CDR of 5q-syndrome, results in macrocytic anemia, a key feature of this syndrome. Mice carrying this chromosomal deletion showed a prominent dysplasia within the erythroid lineage and monolobulated megakaryocytes, as observed by analysis of bone marrow cell morphology. The bone marrow of these mice also showed a marked reduction in the numbers of erythroid and myeloid progenitors; this reduction correlated with the appearance of highly p53-positive bone marrow cells, an elevated incidence of apoptosis and reduced cellularity. A large study of individuals with 5q-syndrome found that the cellularity of the bone marrow in these individuals is variable, with 40% of them having a hypercellular marrow, 40% a normocellular marrow and 20% a hypocellular marrow 2 . Thus, a proportion of individuals with 5q-syndrome have a hypocellular marrow in accord with the hypocellular marrow found in Cd74-Nid67-deleted mice.
Although we noted a mild, but reproducible, reduction in cell numbers or proportions within the myeloid lineages in Lmo2Cre mice, probably due to nonspecific effects resulting from persistent high expression of Cre recombinase 30 , the deficits in these lineages in mice with deletion of the Cd74-Nid67 interval were more profound than those in Lmo2Cre + control mice.
Clearly, haploinsufficiency of a gene (or noncoding sequences) in this region underlies the macrocytic anemia and megakaryocyte dysplasia characteristic of 5q-syndrome. The Cd74-Nid67 interval harbors eight known genes, of which we have excluded the individual involvement of Ndst1 and Cd74, leaving Rps14, Synpo, Myoz3, Dctn4, Rbm22 and Nid67. Of these, the Rps14 gene is a strong candidate, as it has been proposed, using an in vitro RNAi-screening approach, to have a role in 5q-syndrome 15 . Moreover, we have shown that haploinsufficiency of RPS14 in the hematopoietic stem cells of individuals with 5q-syndrome is associated with deregulated expression of multiple ribosomal-and translation-related genes 31 , further supporting the proposal that 5q-syndrome represents a disorder of defective ribosome biogenesis.
The yeast Rps14 homolog is essential for the assembly of 40S ribosomal subunits 32, 33 , although the specific function of RPS14 in humans remains largely unknown. Recent evidence has implicated aberrant ribosomal biogenesis in a number of diseases, including bone marrow failure syndromes 34 . Mutation and resultant haploinsufficiency of a number of ribosomal genes, including those encoding structural components of both the large and small ribosomal subunits, have been identified in Diamond Blackfan anemia 16, 35 , a congenital disease characterized by macrocytic anemia 36 . Furthermore, it has also been suggested that defective ribosomal 60S subunit maturation caused by mutations in the Shwachman-Bodian-Diamond syndrome-associated gene (SBDS) may underlie the hematological dysfunction characteristic of this disease 37 .
We observed that a population of bone marrow cells in Cd74-Nid67-deleted mice expresses higher amounts of p53 than in control mice. Stabilization of p53 is known to lead to apoptosis 27 , and we found that increased bone marrow cell apoptosis was also apparent in these mice. Our finding that introduction of p53 deficiency into Cd74-Nid67-deleted mice completely reverses the observed deficit in bone marrow progenitors and ameliorates the thrombocytopenia of these mice is notable, given the emerging evidence that ribosomal stress leads to activation of the p53 pathway 25, 26, 38 . For example, RPS19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of the p53 protein family 39 . Recently, two mouse dark skin (Dsk) loci with mutations in Rps19 and Rps20 have been reported 25 . The underlying pathophysiology was shown to involve stabilization of p53 leading to c-Kit ligand expression and epidermal melanocytosis. Treacher-Collins syndrome (TCS) is another disorder involving ribosome biogenesis and p53 stabilization. Haploinsufficiency of TCOF1 (encoding treacle, the protein mutated in TCS) 40, 41 perturbs mature ribosome biogenesis 42 , and this has recently been shown to result in the stabilization of p53 (ref. 24) . Inhibition of p53 prevented apoptosis of neuroepithelial cells and rescued the cranioskeletal abnormalities associated with mutations in Tcof1 (ref. 24) .
The genetic data reported here implicate p53 in the molecular mechanism underlying 5q-syndrome. We have previously reported the upregulation of multiple transcriptional targets of p53 in hematopoietic stem cells of individuals with 5q-syndrome, including wildtype p53-induced gene 1 (WIG1); pleckstrin homology-like domain, family a, member 3 (PHLDA3); TNF receptor superfamily, member 6 (FAS); BCL2-associated X protein (BAX); B cell lymphoma/leukemia 11B (BCL11B) and ferredoxin reductase (FDXR) 10, 31 . As postulated for TCS, the ribosome biogenesis checkpoint that leads to activation of p53 function may also provide a therapeutic avenue for the treatment of human 5q-syndrome, although this will be possible only if this checkpoint function can be targeted without affecting the tumor suppressor role of p53. Notably, disruption of 40S ribosome biogenesis leads to p53 induction through a ribosomal protein L11-translation-dependent mechanism that might be targeted therapeutically 43 .
Typically, human myelodysplastic syndromes are associated with thrombocytopenia, as in the mouse model presented here; however, at diagnosis many individuals with 5q-syndrome have normal or slightly elevated platelet counts. The explanation for this apparent difference between the thrombocytopenia observed in the mouse model a r t i c l e s and the lack of thrombocytopenia in individuals with 5q-syndrome is not known; it may be due to a human-mouse species difference or to the presence of additional genetic abnormalities in individuals with 5q-syndrome.
Although our data support a role for Rps14 in 5q-syndrome, it is also possible that other genes in the Cd74-Nid67 interval, together with Rps14, may have additional roles in the disease. For example, Dctn4 encodes dynactin-4, a subunit of the dynactin complex that binds dynein, allowing the motor to migrate on the microtubule lattice. Disruption of dynactin-dynein function can inhibit proplatelet elongation, and this may reduce platelet formation 44 . However, our CFU-MK data suggest that it is a primary defect in megakaryocyte progenitor production that leads to thrombocytopenia in Cd74-Nid67-deleted mice. Rbm22 is highly conserved from yeast to humans and has been proposed to be involved in RNA splicing 45 , aberrations in which have been linked to cancer 46 . Moreover, we have recently shown that individuals with 5q-syndrome show a marked reduction in RBM22 expression (ref. 10) . By contrast, synaptopodin, myozenin-3 and Nid67 seem to be unlikely candidates for proteins whose loss would contribute to 5q-syndrome 47, 48 . It is also possible that loss of other genes, within the CDR but outside of the Cd74-Nid67 interval, could contribute to 5q-syndrome. Future cell transfer studies will help to clarify whether cells carrying the Cd74-Nid67 deletion interval have a competitive survival advantage or whether other genes or mutations are required for clonal survival.
The mouse model of human 5q-syndrome that we describe here will enable both the analysis of emerging therapeutic compounds and the assessment of the mode of action of existing drugs such as lenalidomide. This study shows the feasibility of generating large-scale chromosomal deletions in mice for the genetic analysis of haploinsufficiency in myelodysplasia.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
